TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
FIVE FORCES ANALYSIS 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
LEADING COMPANIES 19
Astra Zeneca 19
GE Healthcare 23
Novartis AG 26
Sanofi-Aventis Group 30
MARKET FORECASTS 34
Market value forecast 34
MACROECONOMIC INDICATORS 35
APPENDIX 37
Methodology 37
Industry associations 38
Related Datamonitor research 38
Disclaimer 39
ABOUT DATAMONITOR 40
Premium Reports 40
Summary Reports 40
Datamonitor consulting 40
LIST OF TABLES
Table 1: United Kingdom biotechnology market value: $ million, 2006–10 10
Table 2: United Kingdom biotechnology market segmentation I:% share, by value, 2010 11
Table 3: United Kingdom biotechnology market segmentation II: % share, by value, 2010 12
Table 4: Astra Zeneca: key facts 19
Table 5: Astra Zeneca: key financials ($) 21
Table 6: Astra Zeneca: key financial ratios 21
Table 7: GE Healthcare: key facts 23
Table 8: GE Healthcare: key financials ($) 24
Table 9: GE Healthcare: key financial ratios 24
Table 10: Novartis AG: key facts 26
Table 11: Novartis AG: key financials ($) 27
Table 12: Novartis AG: key financial ratios 28
Table 13: Sanofi-Aventis Group: key facts 30
Table 14: Sanofi-Aventis Group: key financials ($) 31
Table 15: Sanofi-Aventis Group: key financials (€) 31
Table 16: Sanofi-Aventis Group: key financial ratios 32
Table 17: United Kingdom biotechnology market value forecast: $ million, 2010–15 34
Table 18: United Kingdom size of population (million), 2006–10 35
Table 19: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 35
Table 20: United Kingdom gdp (current prices, $ billion), 2006–10 35
Table 21: United Kingdom inflation, 2006–10 36
Table 22: United Kingdom consumer price index (absolute), 2006–10 36
Table 23: United Kingdom exchange rate, 2006–10 36
LIST OF FIGURES
Figure 1: United Kingdom biotechnology market value: $ million, 2006–10 10
Figure 2: United Kingdom biotechnology market segmentation I:% share, by value, 2010 11
Figure 3: United Kingdom biotechnology market segmentation II: % share, by value, 2010 12
Figure 4: Forces driving competition in the biotechnology market in the United Kingdom, 2010 13
Figure 5: Drivers of buyer power in the biotechnology market in the United Kingdom, 2010 14
Figure 6: Drivers of supplier power in the biotechnology market in the United Kingdom, 2010 15
Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in the United Kingdom, 2010 16
Figure 8: Factors influencing the threat of substitutes in the biotechnology market in the United Kingdom, 2010 17
Figure 9: Drivers of degree of rivalry in the biotechnology market in the United Kingdom, 2010 18
Figure 10: Astra Zeneca: revenues & profitability 22
Figure 11: Astra Zeneca: assets & liabilities 22
Figure 12: GE Healthcare: revenues & profitability 25
Figure 13: GE Healthcare: assets & liabilities 25
Figure 14: Novartis AG: revenues & profitability 28
Figure 15: Novartis AG: assets & liabilities 29
Figure 16: Sanofi-Aventis Group: revenues & profitability 32
Figure 17: Sanofi-Aventis Group: assets & liabilities 33
Figure 18: United Kingdom biotechnology market value forecast: $ million, 2010–15 34
[Inhaltsverzeichnis ausblenden]